<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Grit Biotechnology Announces Closing of 60 Million Series B Financing</title>
    <link rel="stylesheet" href="/static/style.css">
    <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.0.0/dist/css/bootstrap.min.css" integrity="sha384-Gn5384xqQ1aoWXA+058RXPxPg6fy4IWvTNh0E263XmFcJlSAwiGgFAW/dAiS6JXm" crossorigin="anonymous">
    <script src="https://code.jquery.com/jquery-3.2.1.slim.min.js" integrity="sha384-KJ3o2DKtIkvYIK3UENzmM7KCkRr/rE9/Qpg6aAZGJwFDMVNA/GpGFF93hXpG5KkN" crossorigin="anonymous"></script>
    <script src="https://cdn.jsdelivr.net/npm/popper.js@1.12.9/dist/umd/popper.min.js" integrity="sha384-ApNbgh9B+Y1QKtv3Rn7W3mgPxhU9K/ScQsAP7hUibX39j7fakFPskvXusvfa0b4Q" crossorigin="anonymous"></script>
    <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.0.0/dist/js/bootstrap.min.js" integrity="sha384-JZR6Spejh4U02d8jOt6vLEHfe/JQGiRRSQQxSfFWpi1MquVdAyjUar5+76PVCmYl" crossorigin="anonymous"></script>
    <meta id="q" name="global"  />
  </head>
<body>

    <script src="/static/ads.js" ></script>

    <nav class="navbar navbar-expand-lg navbar-dark bg-dark">
        <a class="navbar-brand" href="#">myLogo</a>
        <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarSupportedContent" aria-controls="navbarSupportedContent" aria-expanded="false" aria-label="Toggle navigation">
          <span class="navbar-toggler-icon"></span>
        </button>
      
        <div class="collapse navbar-collapse" id="navbarSupportedContent">
          <ul class="navbar-nav mr-auto">
            <li class="nav-item active">
              <a class="nav-link" href="#">Home <span class="sr-only">(current)</span></a>
            </li>
          </ul>
          <form class="form-inline my-2 my-lg-0" method="GET" action="/search">
            <input id="query" class="form-control mr-sm-2" type="search" placeholder="Search" aria-label="Search">
            <button class="btn btn-outline-success my-2 my-sm-0" type="button" onclick="search()">Search</button>
          </form>
        </div>
      </nav>

        <div id="mainad"><a href=""><img src="" alt="banner"></a> </div>


    <div id="wrapper">

        <div id="main">
            <p id="title">Grit Biotechnology Announces Closing of 60 Million Series B Financing</p>
            <div id="meta"><b>cision</b><i> 2023-09-08 09:00:00</i></div>
            <img src="https://mma.prnewswire.com/media/2205351/20230908140547_Logo.jpg?p=original" alt="source_page">
            <a href="https://www.prnewswire.com/news-releases/grit-biotechnology-announces-closing-of-60-million-series-b-financing-301921744.html"><u>Source page </u></a>
            <hr>
            <div id="content">
                 PRNewswire  On  ounced the completion of a Series B financing round raising over  The investment was led by CICC with participation from Qianhai Ark Liando Group Yuanhe Capital HeFangTian Venture Partnership and existing investors Sherpa Healthcare Partners Decheng Capital and Matrix Partners China The financing will support Grit Biotechnologys TumorInfiltrating Lymphocyte TIL pipeline development including the pivotal Phase II trial for GT101 and the advancement of nextgen geneedited TIL products Founded in 2019 Grit Biotechnology is a pioneering cell therapy company focused on delivering transformative cancer treatments GT101 is currently the fastestdeveloping TIL therapy in and will enter a Phase II trial by the end of 2023 has four core technology platforms central to its TIL development StemTexp  StaViral  KOReTIL and ImmuT Finder  a genomewide CRISPRCas9 screening platform These platforms have enabled the development of nextgeneration geneedited TIL products GT201 a genetically engineered TIL product by Grit Biotechnology boosts T cell survival and function by expressing a vital membranebound cytokine It surpasses traditional TIL therapies in proliferation tumorkilling and persistence with reduced reliance on IL2 GT201 IND is approved by CFDA and entered Phase I clinical trials GT316 Grit Biotechnologys nextgen TIL product enhances TIL performance through knockout of immunoregulatory targets identified via ImmuT Finder CRISPRCas9 screening In PDX mouse models GT316 effectively eliminates tumors supported by lowdose IL2 support with minimal toxicity It offers substantial clinical benefits compared to conventional TIL products and is currently in IIT clinical trials in  With 100 experienced professionals and a 10000 sqm GMPlevel cell therapy manufacturing facility in Suzhou  is a leading player in cell therapy field in aimed at expediting the development of GT101 and nextgeneration TIL pipelines and addressing the unmet medical needs of solid tumor patients CICC Capital is the flagship platform of China International Capital Corporation Limited CICC for its global private equity businesses and has become a leading internationally influential comprehensive alternative investment brand in  Currently CICC Capital runs various categories of RMB private equity funds including real estate and infrastructure fund of funds and USD private equity funds Qianhai Ark Asset Management Co Ltd is one of the leading and toptier fund managers in  jointly founded by Mr Jin Haitao a representative figure in venture capital industry who currently serves as the Vice Chairman of the Asset Management Association of  and Shenzhen Capital Group SCGC along with leaders from the financial investment industry The company is headquartered in  with branch offices in     and other cities Qianhai Ark currently manages its funds portfolio includes FOFs regional funds and specialized funds and manages nearly in assets Qianhai Ark covers various sectors such as information technology life sciences and advanced manufacturing Qianhai Ark possesses a vast industrial resource pool facilitating industrial synergy and providing substantial support to its portfolio companies Liando Group was founded in 1991 focusing on industrial services and park operations It has developed into an industrial conglomerate with nationwide influence Its core enterprise Liando U Valley currently invests and operates 432 industrial parks in 83 cities across the country providing services to over 16000 emerging manufacturing and technologyoriented companies Liando Group strategically directs its equity funds through direct investment and venture capital to key emerging industrial areas such as life sciences intelligent manufacturing and digital technology Yantai Yuanhe Capital hereinafter referred to as Yuanhe Capital was established in 2019 as the equity management institution for external investments of Yantai Financial Development Group Co Ltd hereinafter referred to as Yantai Financial Group As of 2023 Yuanhe Capital has successfully launched 17 funds managing a total fund size exceeding and engaging in over 154 investment projects Yuanhe Capital specializes in providing comprehensive entrepreneurial support and investment opportunities in various sectors including semiconductors biopharmaceuticals and advanced manufacturing As a dedicated value investor Yuanhe Capital upholds the core principles of trust value sharing and cooperation The firms primary goal is to invest in and assist visionary and creative entrepreneurs in realizing their entrepreneurial aspirations with success SOURCE Grit Biotechnology
            </div>
        </div>
        <div id="related"></div>
    </div>

    <script type="text/javascript" src="/static/script.js" ></script>

</body>
</html>